HIV

BINAV® (emtricitabine + tenofovir disoproxil fumarate)

  • ACTIVE INGREDIENT: emtricitabine + tenofovir disoproxil fumarate
  • CONCENTRATION: 200 mg and 300 mg
  • PRESENTATION: 30 coated tablets

INDICATION:

BINAV (emtricitabine + tenofovir disoproxil fumarate) is indicated:

  • In combination with other anti-HIV drugs for the treatment of HIV-1 infection in adults.
  • In combination with safe sex practices as part of pre-exposure prophylaxis to reduce the risk of sexually acquired HIV infection in high-risk adults and adolescents aged 15 years and older and weighing 35 kg or more.
  • HIV-negative men who have sex with men, who are at high risk for HIV-1 infection through sex.
  • Male-female sex partners when one partner has HIV-1 infection and the other does not.

They are indicative of high risk in men who have sex with men and in heterosexual men and women:

  • Having an HIV-positive sexual partner.
  • DST (Enfermedades Sexualmente Transmisibles) bacteriana reciente.
  • Recent bacterial STD (Sexually Transmissible Diseases).
  • High number of sexual partners.
  • History of unconscious or non-use of condoms.
  • Sexual work.
  • Partner(s) with unknown HIV-1 status and any of the above factors.

WHERE TO FIND

PRIVATE MARKET

Insira seu cep e confira as lojas mais próximas de você!

*Item não encontrado, tente novamente.

CONTRAINDICATIONS:

Do not take BINAV if you are allergic to BINAV or to any of its ingredients. The active ingredients in BINAV are emtricitabine and tenofovir DF.

Do not take BINAV (emtricitabine + tenofovir disoproxil fumarate) if you are also taking any of the medicines listed below:

• Emtricitabine or tenofovir. These medicines contain the same active ingredient as BINAV (emtricitabine + tenofovir disoproxil fumarate).
• Medicines containing lamivudine or tenofovir alafenamide or adefovir (HEPSERA®).

For people taking BINAV (emtricitabine + tenofovir disoproxil fumarate) for pre-exposure prophylaxis to reduce the risk of HIV-1 infection:

BINAV (emtricitabine + tenofovir disoproxil fumarate) can only help reduce your risk of becoming infected with HIV-1 before you become infected. Do not take BINAV (emtricitabine + tenofovir disoproxil fumarate) for pre-exposure prophylaxis to help reduce your risk of becoming infected with HIV-1 if:

• You already have HIV-1 infection. If you are HIV positive, you must take other medicines used to treat HIV-1 together with BINAV (emtricitabine + tenofovir disoproxil fumarate). BINAV (emtricitabine + tenofovir disoproxil fumarate) alone is not a complete treatment for HIV-1.
• You do not know your HIV-1 infection status. You may already be HIV-positive. You need to take other HIV-1 medications with BINAV (emtricitabine + tenofovir disoproxil fumarate) to treat HIV-1.

Category B: This medicine should not be used by pregnant women without guidance from a doctor or surgeon-dentist.

  • FOLLOW US ON SOCIAL MIDIAS:

Rua Joaquim Faustino de Camargo, 201, Jardim São Paulo, Taboão da Serra - SP (11) 4138-8200 • © Blanver 2020, Todos os direitos reservados